Laura Alder, Medical Oncology Deputy Director at Duke Center for Brain and Spine Metastasis, shared a post on LinkedIn:
“I’m honored and grateful to have been selected as an ASCO26 Featured Voice! It’s going to be an incredible meeting! From practice-changing lung cancer trials to landmark plenary sessions across oncology, there is SO much to cover.
A few highlights I’m watching closely:
Lung Cancer: From sunvozertinib in EGFR exon 20 insertion NSCLC (WU-KONG28) to ivonescimab in squamous NSCLC (HARMONi-6), adjuvant selpercatinib in RET fusion+ disease (LIBRETTO-432), ALCHEMIST adjuvant nivolumab data, 7-year CROWN lorlatinib follow-up, and novel combinations targeting KRAS G12C and STK11/KEAP1. The lung cancer sessions alone could reshape how we treat patients across multiple settings.
A Focus on SCLC: Concurrent TRT with chemo/durvalumab in ES-SCLC, tarlatamab intracranial data (DeLLphi-304), and novel agents in relapsed/refractory disease round out a packed oral session.
I’ll be sharing my insights, key takeaways, and what I believe will be practice-changing throughout the meeting. Follow along using ASCO26!
Grateful for this opportunity to contribute to the conversation and bring the science back to the clinic.
Graphics in the gallery by Aakash Desai and Estelamari Rodriguez.”
